Moderna, Inc. (NASDAQ:MRNA) Shares Bought by APEIRON CAPITAL Ltd

APEIRON CAPITAL Ltd increased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 96.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 31,200 shares of the company's stock after buying an additional 15,300 shares during the quarter. Moderna comprises approximately 4.6% of APEIRON CAPITAL Ltd's portfolio, making the stock its 7th biggest holding. APEIRON CAPITAL Ltd's holdings in Moderna were worth $3,103,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of Moderna by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 27,658,449 shares of the company's stock worth $2,856,841,000 after purchasing an additional 196,012 shares during the period. Geode Capital Management LLC grew its stake in shares of Moderna by 1.3% in the first quarter. Geode Capital Management LLC now owns 6,244,957 shares of the company's stock valued at $957,063,000 after buying an additional 77,265 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Moderna by 9.3% in the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company's stock valued at $579,572,000 after buying an additional 476,201 shares in the last quarter. Morgan Stanley grew its stake in shares of Moderna by 19.1% in the fourth quarter. Morgan Stanley now owns 4,187,353 shares of the company's stock valued at $752,133,000 after buying an additional 670,284 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Moderna by 77.3% in the third quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company's stock valued at $400,367,000 after buying an additional 1,690,341 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Stock Performance

NASDAQ:MRNA traded down $0.59 during trading hours on Friday, reaching $101.41. 2,670,446 shares of the stock were exchanged, compared to its average volume of 3,130,469. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. The firm has a 50 day simple moving average of $100.63 and a 200-day simple moving average of $93.57. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $144.43. The stock has a market capitalization of $38.83 billion, a P/E ratio of -8.17 and a beta of 1.62.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $1.33. The business had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The business's revenue was down 44.9% on a year-over-year basis. During the same quarter last year, the business posted $3.61 EPS. As a group, sell-side analysts forecast that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on MRNA shares. William Blair reiterated a "market perform" rating on shares of Moderna in a research note on Monday, April 1st. Jefferies Financial Group reiterated a "buy" rating and issued a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer upgraded Moderna from a "market perform" rating to an "outperform" rating and set a $142.00 price objective for the company in a research note on Tuesday, January 2nd. Needham & Company LLC restated a "hold" rating on shares of Moderna in a research note on Thursday, April 11th. Finally, Canaccord Genuity Group raised their price objective on Moderna from $82.00 to $91.00 and gave the company a "hold" rating in a research note on Friday, February 23rd. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Hold" and an average target price of $126.49.

Insider Buying and Selling

In related news, CFO James M. Mock sold 647 shares of the firm's stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company's stock, valued at approximately $406,651. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now owns 4,300 shares of the company's stock, valued at approximately $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO James M. Mock sold 705 shares of Moderna stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares in the company, valued at approximately $514,542.64. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 109,954 shares of company stock valued at $11,533,976. Insiders own 15.70% of the company's stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.